Repatha Was Almost Derailed By Formulation Bridging Concerns
FDA's worries about sufficiency of long-term safety data were exacerbated by 'weak' bridging data between two formulations; agency decided against refuse-to-file action but directed Amgen to immediately begin new PK/PD study.
You may also be interested in...
A listing of the Drug Review Profile series articles published in the Pink Sheet.
Sanofi and Regeneron's 'extended negotiations' with FDA on requirements would later apply to Amgen's Repatha.
MedWatch report of hepatotoxicity prompted two 'urgent information requests' to sponsors a month before alirocumab user fee goal date.